Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Intangibles: 2022-2025

Historic Intangibles for Rocket Pharmaceuticals (RCKT) over the last 3 years, with Sep 2025 value amounting to $25.1 million.

  • Rocket Pharmaceuticals' Intangibles changed negligibly% to $25.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.1 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $25.1 million for FY2024, which is negligibly% changed negligibly from last year.
  • Rocket Pharmaceuticals' Intangibles amounted to $25.1 million in Q3 2025, which was down 0.00% from $25.1 million recorded in Q2 2025.
  • In the past 5 years, Rocket Pharmaceuticals' Intangibles ranged from a high of $25.7 million in Q4 2022 and a low of $25.1 million during Q3 2023.
  • Its 3-year average for Intangibles is $25.3 million, with a median of $25.1 million in 2025.
  • Data for Rocket Pharmaceuticals' Intangibles shows a maximum YoY declined of 2.23% (in 2023) over the last 5 years.
  • Rocket Pharmaceuticals' Intangibles (Quarterly) stood at $25.7 million in 2022, then fell by 2.23% to $25.1 million in 2023, then remained steady at $25.1 million in 2024, then remained steady at $25.1 million in 2025.
  • Its last three reported values are $25.1 million in Q3 2025, $25.1 million for Q2 2025, and $25.1 million during Q1 2025.